<DOC>
	<DOCNO>NCT00607971</DOCNO>
	<brief_summary>The main purpose study evaluate long-term safety tolerability renzapride dose 4 mg take daily 12 month woman constipation-predominant irritable bowel syndrome ( IBS-C ) .</brief_summary>
	<brief_title>Long-Term Safety Renzapride Women With Constipation-Predominant Irritable Bowel Syndrome ( IBS-C )</brief_title>
	<detailed_description>Since IBS chronic condition affect patient many year , anticipate renzapride prescribed use patient daily basis long periods time . Hence need understand long-term safety tolerability target population . This study open label subject take renzapride know take . Enrolment study restrict subject complete 12-week , placebo-controlled study effectiveness renzapride provide relief IBS-C ( Study . ATL1251/038/CL ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Renzapride</mesh_term>
	<criteria>complete 12 week treatment precede pivotal study ATL1251/038/CL Subjects pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Constipation predominant irritable bowel syndrome</keyword>
</DOC>